Curaleaf (TSX: CURA, OTCQX: CURLF) reported second quarter 2026 net revenue of $340.1 million, up 10% year-over-year and 5% sequentially. Domestic revenue was $288.7 million and international revenue $51.4 million. Gross profit reached $169.9 million with a 50% gross margin, up 70 basis points year-over-year.
Net income from continuing operations attributable to Curaleaf was $12.5 million, or $0.05 per share. Adjusted EBITDA was $70.1 million, with a 20.6% margin, down 120 basis points year-over-year. For the first half of 2026, net revenue was $664.3 million (+8% year-over-year) and gross profit $327.2 million (49% margin). The company ended the quarter with $107.0 million in cash and $611.5 million of outstanding debt, invested $32.9 million in capex, and repurchased 1.01 million shares for $7.4 million. Operationally, Curaleaf expanded its Florida retail footprint, launched its Dark Heart brand in 11 states, completed the buyout of the remaining 45% of Four20 Pharma, and noted post-quarter approvals for two cannabis medicines in Spain.